Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

632
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
632
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

665
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
665
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

183
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
183
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

166
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
166
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

528
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
528
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

645
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
645

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Learning Topology-Aware Representations via Test-Time Adaptation for Anomaly Segmentation.

IEEE transactions on pattern analysis and machine intelligence·2026
Same author

Computer-aided design, molecular dynamics simulations and in-vitro inhibitory potential of piperazine bridged bis-thiadiazole benzothioate derivatives against platelet-derived endothelial cell growth factor.

Journal of computer-aided molecular design·2026
Same author

Phytohormones producing endophytic fungi Paecilomyceslilacinus modulated metabolic, enzymatic, and non-enzymatic antioxidant systems of Zea mays L. under heavy metal stress.

BMC plant biology·2026
Same author

Fault tolerance in para-line network topologies: theory and applications in smart systems.

Scientific reports·2026
Same author

Re-Profiling and Re-purposing of FDA-Approved AntiViral Agents Against Neurological Targets of Memory and Cognition: Molecular Docking and Simulation Approach.

CNS & neurological disorders drug targets·2026
Same author

Enhancing Cloud-Based Healthcare Security With Quantum-Secure HealthChain: A Quantum Computing and Blockchain Integrated Framework.

Health science reports·2026

Related Experiment Video

Updated: Jul 6, 2025

A Rat Carotid Balloon Injury Model to Test Anti-vascular Remodeling Therapeutics
08:42

A Rat Carotid Balloon Injury Model to Test Anti-vascular Remodeling Therapeutics

Published on: September 19, 2016

8.7K

Atorvastatin as an Antihypertensive Agent: A Pilot Study.

Niaz Ali1, Muhammad Faheem2, Himayat Ullah3

  • 1Pharmacology, College of Medicine, Shaqra University, Shaqra, SAU.

Cureus
|December 29, 2023
PubMed
Summary

Adding atorvastatin to amlodipine significantly lowers blood pressure in hypertensive patients. This study explored the antihypertensive effects of statins, showing improved blood pressure control when combined with standard treatment.

Keywords:
anti-hypertensiveatorvastatincalcium channel blockershypercholesterolemiahypertensionstatins

More Related Videos

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

12.2K
Multiple Intravenous Bolus Dosing and Invasive Hemodynamic Assessment in a Hypoxia-Induced Mouse Pulmonary Artery Hypertension Model
08:51

Multiple Intravenous Bolus Dosing and Invasive Hemodynamic Assessment in a Hypoxia-Induced Mouse Pulmonary Artery Hypertension Model

Published on: November 11, 2022

1.5K

Related Experiment Videos

Last Updated: Jul 6, 2025

A Rat Carotid Balloon Injury Model to Test Anti-vascular Remodeling Therapeutics
08:42

A Rat Carotid Balloon Injury Model to Test Anti-vascular Remodeling Therapeutics

Published on: September 19, 2016

8.7K
An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

12.2K
Multiple Intravenous Bolus Dosing and Invasive Hemodynamic Assessment in a Hypoxia-Induced Mouse Pulmonary Artery Hypertension Model
08:51

Multiple Intravenous Bolus Dosing and Invasive Hemodynamic Assessment in a Hypoxia-Induced Mouse Pulmonary Artery Hypertension Model

Published on: November 11, 2022

1.5K

Area of Science:

  • Cardiology
  • Pharmacology
  • Internal Medicine

Background:

  • Hypertension (HTN) is a leading cause of chronic disease and a major risk factor for cardiovascular and cerebrovascular events.
  • Hypertension frequently coexists with dyslipidemia, presenting a complex clinical challenge.
  • Statins, primarily used for lipid-lowering, have demonstrated potential antihypertensive effects in preclinical models.

Purpose of the Study:

  • To investigate the antihypertensive efficacy of atorvastatin in patients with newly diagnosed hypertension.
  • To determine if statins possess voltage-gated calcium channel-blocking properties relevant to blood pressure reduction.
  • To evaluate the additive effect of atorvastatin on amlodipine-induced blood pressure lowering.

Main Methods:

  • A randomized controlled trial was conducted with 120 newly diagnosed hypertensive patients (aged 35+).
  • Patients were randomized into two groups: Group 1 received amlodipine 5 mg daily, and Group 2 received amlodipine 5 mg plus atorvastatin 10 mg daily.
  • Blood pressure was measured at baseline and after a 14-day follow-up period.

Main Results:

  • Both groups showed reductions in blood pressure, but Group 2 (amlodipine + atorvastatin) exhibited significantly lower systolic and diastolic blood pressures compared to Group 1 (amlodipine alone) at the 14-day follow-up (p≤0.05).
  • The study included a balanced gender distribution (53.3% males, 46.7% females) with a mean age of 51.07 years.
  • The findings indicate a statistically significant benefit of adding atorvastatin to amlodipine therapy.

Conclusions:

  • The addition of atorvastatin, a lipid-lowering agent, to amlodipine significantly enhances blood pressure reduction in hypertensive individuals.
  • This suggests a potential adjunctive role for statins in managing hypertension, particularly in patients with coexisting dyslipidemia.
  • Further research may explore the mechanisms behind statin-induced blood pressure lowering and long-term clinical outcomes.